Craig A. Portell, MD, discusses the current standard of care for patients with relapsed/refractory mantle cell lymphoma and how sequencing therapies changed the landscape of mantle cell lymphoma treatment.
Craig A. Portell, MD
Advertisement
Craig A. Portell, MD, holds a clinical faculty appointment in medicine in the Division of Hematology/Oncology at the University of Virginia. He practices at the Emily Couric Clinical Cancer Center in Charlottesville and serves as an inpatient hematologist at UVA Health.
Articles by Craig A. Portell, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
